- Home
- NAMS vs CSQ Comparison
NAMS vs CSQ Comparison
Compare NAMS & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- CSQ
- Stock Information
- Founded
- NAMS 2019
- CSQ 2003
- Country
- NAMS Netherlands
- CSQ United States
- Employees
- NAMS N/A
- CSQ N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- CSQ Finance Companies
- Sector
- NAMS Health Care
- CSQ Finance
- Exchange
- NAMS Nasdaq
- CSQ Nasdaq
- Market Cap
- NAMS 2.5B
- CSQ 2.8B
- IPO Year
- NAMS N/A
- CSQ N/A
- Fundamental
- Price
- NAMS $19.85
- CSQ $18.44
- Analyst Decision
- NAMS Strong Buy
- CSQ
- Analyst Count
- NAMS 8
- CSQ 0
- Target Price
- NAMS $42.88
- CSQ N/A
- AVG Volume (30 Days)
- NAMS 1.0M
- CSQ 220.3K
- Earning Date
- NAMS 08-06-2025
- CSQ 01-01-0001
- Dividend Yield
- NAMS N/A
- CSQ 7.53%
- EPS Growth
- NAMS N/A
- CSQ N/A
- EPS
- NAMS N/A
- CSQ N/A
- Revenue
- NAMS $47,140,000.00
- CSQ N/A
- Revenue This Year
- NAMS N/A
- CSQ N/A
- Revenue Next Year
- NAMS N/A
- CSQ N/A
- P/E Ratio
- NAMS N/A
- CSQ N/A
- Revenue Growth
- NAMS 586.97
- CSQ N/A
- 52 Week Low
- NAMS $14.06
- CSQ $12.50
- 52 Week High
- NAMS $27.29
- CSQ $16.45
- Technical
- Relative Strength Index (RSI)
- NAMS 52.90
- CSQ 72.29
- Support Level
- NAMS $17.97
- CSQ $18.07
- Resistance Level
- NAMS $19.13
- CSQ $18.40
- Average True Range (ATR)
- NAMS 1.04
- CSQ 0.23
- MACD
- NAMS -0.03
- CSQ 0.04
- Stochastic Oscillator
- NAMS 35.63
- CSQ 91.15
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.